Minimal residual disease

Current Opinion in Hematology

Volumn 5, Issue 6, 1998, Pages 488-493

  Negrin, Robert S ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; T LYMPHOCYTE RECEPTOR;

ARTICLE; DIAGNOSTIC PROCEDURE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; LEUKEMIA; MEDICAL DECISION MAKING; MINIMAL RESIDUAL DISEASE; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0031743306     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199811000-00023     Document Type: Article

References (24)

1. Tkachuk DC, Westbrook CA, Andreef M, et al. Detection of bcr-abl fusion in chronic myelogenous leukaemia by in situ hybridisation. Science 1990, 250:559-562.
2. Sinclair PB, Green AR, Grace C, Nacheva EP. Improved sensitivity of BCR-ABL detection: a triple-probe three-color fluorescence in situ hybridization system. Blood 1997, 90:1395-1402. This study describes the use of a third probe labelled with a different fluorochrome that permits the identification of the Philadelphia chromosome with a lower rate of false positive results than conventional FISH techniques.
3. Dewald GW, Wyatt WA, Juneau AL, et al. Highly sensitive fluorescence in situ hybridization method to detect double bcr/abl fusion and monitor response to therapy in chronic myeloid leukemia. Blood 1998, 91:3357-3365. In this study a new method of FISH is described in which DNA probes that span the common breakpoints of the Philadelphia chromosome are used, which detect double fusions in true positives, thereby decreasing the false positive rate and increasing the sensitivity of MRD detection.
4. Viswanatha DS, Chen I, Liu PP, et al. Characterization and use of an antibody detecting the CBFbeta-SMMHC fusion protein in inv16/t(16;16)-associated acute myeloid leukemias. Blood 1998, 91:1882-1890.
5. Taube T, Seeger K, Beyermann B, et al. Multiplex PCR for simultaneous detection of the most frequent T cell receptor-delta gene rearrangements in childhood ALL. Leukemia 1997, 11:1978-1982.
6. Voena C, Ladetto M, Astolfi M, et al. A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors. Leukemia 1997, 11:1793-1798.
7. Haber M, Kwan E, Zhu L, Marshall GM, Morris MD. Sensitive non-radioactive PCR detection of clonal T-cell receptor-gamma gene rearrangements in childhood acute lymphoblastic leukemia. Br J Haematol 1997, 98:995-998.
8. Kurokawa T, Kinoshita T, Murate T, et al. Complementarity determining region-III is a useful molecular marker for the evaluation of minimal residual disease in mantle cell lymphoma. Br J Haematol 1997, 98:408-412.
9. Martin G, Mairs RJ. Synthesis of quantitation standards for nested competitive PCR for the determination of minimal residual disease in B-lineage acute lymphoblastic leukaemia. Leuk Res 1997, 21:807-809.
10. Dibenedetto SP, Lo Nigro L, Mayer SP, Rovera G, Schiliro G. Detectable molecular residual disease at the beginning of maintenance therapy indicates a poor outcome in children with T-cell acute lymphoblastic leukemia. Blood 1997, 90:1226-1232, An important study that uses TCR rearrangements to detect MRD. In this study it was observed that the presence of MRD was a strong predictor of a poor outcome at several distinct time points. Results from MRD assays performed in this manner may allow for the appropriate aggressive treatment of patients who are at high risk of relapse.
11. Goulden NJ, Knechtli CJ, Garland RJ, et al. Minimal residual disease analysis for the prediction of relapse in children with standard-risk acute lymphoblastic leukaemia. Br J Haematol 1998, 100:235-244.
12. Jacquy C, Delepaut B, Van Daele S, et al. A prospective study of minimal residual disease in childhood B-lineage acute lymphoblastic leukaemia: MRD level at the end of induction is a strong predictive factor of relapse. Br J Haematol 1997, 98:140-146.
13. Brisco MJ, Sykes PJ, Hughes E, et al. Monitoring minimal residual disease in peripheral blood in B-lineage acute lymphoblastic leukaemia. Br J Haematol 1997, 99:314-319.
14. Leonard BM, Hetu F, Busque L, et al. Lymphoma cell burden in progenitor cell grafts measured by competitive polymerase chain reaction: less than one log difference between bone marrow and peripheral blood sources. Blood 1998, 91:331-339.
15. Lopez-Guillermo A, Cabanillas F, McLaughlin P, et al. The clinical significance of molecular response in indolent follicular lymphomas. Blood 1998, 91:2955-2960. A large study of 194 previously untreated patients with follicular NHL who were analyzed for MRD using t(14;18) PCR. Results from this study indicate that this assay of MRD, along with the β2-microglobulin level, were strong predictors of outcome in patients with this disease.
16. Laczika K, Novak M, Hilgarth B, et al. Competitive CBFbeta/MYH11 reverse-transcriptase polymerase chain reaction for quantitative assessment of minimal residual disease during postremission therapy in acute myeloid leukemia with inversion (16): a pilot study. J Clin Oncol 1998, 16:1519-1525.
17. Elmaagacli AH, Beelen DW, Kroll M, Trzensky S, Stein C, Schaefer UW. Detection of CBFbeta/MYH11 fusion transcipts in patients with inv(16)acute myeloid leukemia after allogeneic bone marrow or peripheral cell transplantation. Bone Marrow Transplant 1998, 21:159-166.
18. Meloni G, Diverio D, Vignetti M, et al. Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of PML/RAR alpha fusion gene. Blood 1997, 90:1321-1325, In this study of 15 patients with the M3 subtype of acute myelocytic leukemia, the finding of PCR-positive disease prior to autografting strongly predicted for a poor outcome following an autologous transplantation in second complete remission. In contrast, those patients in second complete remission who were PCR negative prior to transplantation fared well.
19. Radich JP, Gehly G, Gooley T, et al. Polymerase chain reaction of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. Blood 1995, 85:2632-2638.
20. Drobyski WR, Endean DJ, Klein JP, Hessner MJ. Detection of BCR/ABL RNA transcripts using the polymerase chain reaction is highly predictive for relapse in patients transplanted with unrelated marrow grafts for chronic myelogenous leukaemia. Br J Haematol 1997, 98:458-466.
21. Lopez M, Lemoine FM, Firat H, et al. Bone marrow versus peripheral blood progenitor cells CD34 selection in patients with non-Hodgkin's lymphomas: different levels of tumor cell reduction. Implications for autografting. Blood 1997, 90:2830-2838.
22. Andersen NS, Donovan JW, Borus JS, et al. Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease. Blood 1997, 90:4212-4221.
23. Coustan-Smith E, Behm FG, Sanchez J, et al. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet 1997, 351:550-554. In this study multiparamatric cell sorting was used to detect cells with leukemia-associated phenotypes in children with ALL. This assay was capable of detecting 1 cell in 10,000. Detectable leukemia was associated with subsequent relapse at a highly statistically significant level.
24. 3 residual tumor cells in a first remission BM sample had a significantly greater chance of subsequent relapse and a lower median relapse-free survival than those patients with less disease.